Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Oncology Exam 3 > Multiple Myeloma > Flashcards

Multiple Myeloma Flashcards

1
Q 
The median age at diagnosis of multiple myeloma is:
A. 39
B. 49
C. 59
D. 69
E. 79
A

D. 69

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

True or False: MM affects men slightly more than women, and African American have twice the incidence and mortality as Caucasians.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which type of cells does multiple myeloma affect?

A

Terminally differentiated B cells (plasma cells)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q 
Interleukin-\_\_ (IL-\_\_) is a growth factor that promotes the survival of the Multiple Myeloma cell.
A. 2
B. 3
C. 4
D. 5
E. 6
A

E. 6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Multiple myeloma cells secrete IL-__, IL-___, and the soluble IL-6 receptor that activate osteoclasts in the vicinity of the myeloma cell to cause bone resorption

A

IL-1 and IL-6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

True or False: Patients with Multiple Myeloma present with an increase in blood vessel density, with elevated basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF).

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

In the model of disease progression for multiple myeloma, which of the following is the correct order?
A. Multiple myeloma, smoldering myeloma, normal plasma cell, monoclonal gammopathy of undetermined significance (MGUS)
B. Normal plasma cell, smoldering myeloma, MGUS, multiple myeloma
C. Normal plasma cell, MGUS, multiple myeloma, smoldering myeloma
D. Normal plasma cell, MGUS, smoldering myeloma, multiple myeloma

A

D. Normal plasma cell, MGUS, smoldering myeloma, multiple myeloma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

True or False: Early initiation of chemotherapy in the MGUS and smoldering myeloma stages has been shown to improve outcomes.

A

False! It did not improve outcomes, so observe patient and begin treatment when symptomatic.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

True or False: With multiple myeloma, there is increased bone resorption.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

The easy way to remember how multiple myeloma patients present is by using the acronym CRAB. What does each letter stand for?

A 
C = Increased calcium above 11.5
R = Renal function decrease (Scr > 2)
A = Anemia (hemoglobin < 10 or 2 g below lower limit of normal)
B = Lytic bone lesions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

________ are plasma cell tumors that arise outside the bone marrow in multiple myeloma.

A

Extramedullary plasmacytomas (EMPs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

_______ is the most common site that extramedullary plasmacytomas (EMPs) in multiple myeloma occur, but may present in any organ.

A

Upper Respiratory Tract

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Of the initial workup for multiple myeloma, all of the following are extremely important and should be focused on EXCEPT:
A. Skeletal survey
B. Bone marrow aspirate/biopsy
C. Serum protein electrophoresis (SPEP)
D. 24-hr urine for urine protein electrophoresis (UPEP)

A

A. Skeletal survey (this is also a test that can be done, but she said to focus on the other 3).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which of the following types of multiple myeloma is the most common?
A. Heavy chain (IgG, IgA, IgM)
B. Light chain (Kappa or lambda)
C. Non-secretory

A

A. Heavy chain (IgG, IgA, IgM)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which of the following types of multiple myeloma has no detectable immunoglobulin?
A. Heavy chain (IgG, IgA, IgM)
B. Light chain (Kappa or lambda)
C. Non-secretory

A

C. Non-secretory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Patients with which of the following types of multiple myeloma are at higher risk for hyperviscosity?
A. Heavy chain (IgG, IgA, IgM)
B. Light chain (Kappa or lambda)
C. Non-secretory

A

B. Light chain (Kappa or lambda)

17
Q

~ 20% of patients with MM produce light chains only, which are incomplete immunoglobulins. Light chain proteins can cause ______ proteinuria, which is when they are secreted in the urine and cause kidney damage as well.

A

Bence jones

18
Q

The serum protein electrophoresis (SPEP) is used in diagnosing multiple myeloma patients by assessing for a sharp peak of the gamma region called the ______.

A

M Spike

19
Q

True or False: Smoldering myeloma patients are often symptomatic, which is why we must start chemotherapy at that stage.

A

False!! Smoldering myeloma is asymptomatic so only observe patients until they become symptomatic with active myeloma.

20
Q

The M protein level for MGUS stage should be < __ g/dL

A

3

21
Q

Describe how each stage of multiple myeloma presents in terms of level of M protein, % of plasma cells, and symptomatic or asymptomatic stage.

A

MGUS = Asymptomatic, < 10% PC, M-protein < 3 g/dL
Smoldering myeloma = Asymptomatic, M-protein ≥ 3 g/dL, and ≥ 10% PC
Active Multiple Myeloma = Symptomatic (CRAB) + M spike + ≥ 10% PC

22
Q

True or False: Multiple myeloma is NOT curable.

A

True

23
Q

True or False: Lenalidomide treatment may need to be adjusted for renal dysfunction.

A

True

24
Q

With lenalidomide treatment for multiple myeloma, a decrease in CD34+ cells collected after prolonged lenalidomide treatment has been reported. Therefore, have stem cells collectedwithin the first __ cycles of therapy, if deemed transplant-eligible

A

4

25
Q

List some of the common adverse effects of lenalidomide.

A 
Peripheral neuropathy
Neutropenia
Thrombocytopenia
Thromboembolic clots
Fatigue
26
Q

True or False: Bortezomib dose has to be adjusted in patients with renal dysfunction.

A

False! It has to be adjusted in patients with hepatic dysfunction.

27
Q

Which should be used in combination therapy for multiple myeloma: low-dose dexamethasone OR high-dose dexamethasone?

A

Low-dose dexamethasone

28
Q 
Which of the following is the WORST side effect seen with the protease inhibitor bortezomib?
A. Peripheral neuropathy
B. Hypotension
C. Fatigue
D. Myelosuppression
A

A. Peripheral neuropathy

29
Q

Which of the following formulations of bortezomib was shown to have lower peripheral neuropathy risk: IV OR subcutaneous

A

Subcutaneous

30
Q

List some factors that would make someone NOT a candidate for transplantation in multiple myeloma.

A

Age > 77 years old
Direct bili > 2.0
ECOG 3 or 4
NYHA class 3 or 4

31
Q

_____ can cause herpes zoster reactivation.
A. Proteasome inhibitors (bortezomib, carfilzomib, ixazomib)
B. Anti-CD20 monoclonal antibody (Rituximab)
C. Immunomodulatory agents (Thalidomide, Lenalidomide, Pomalidomide)
D. All of the above

A

A. Proteasome inhibitors (bortezomib, carfilzomib, ixazomib)

32
Q

For transplant eligible multiple myeloma patients, there are 3 preferred 3-drug regimens. List them.

A

Bortezomib + lenalidomide + dexamethasone
Bortezomib + doxorubicin + dexamethasone
Bortezomib + cyclophosphamide + dexamethasone

33
Q

For transplant eligible multiple myeloma patients, if the patient cannot tolerate a 3-drug regimen, what is an appropriate 2 drug regimen?

A

Bortezomib + dexamethasone

34
Q

When comparing high dose vs. low dose dexamethasone in multiple myeloma patients, what were 3 common adverse effects seen more frequently in patients on high dose vs. low dose?
A. DVT, infections, hepatitis B reactivation
B. Infections, fatigue, hand foot syndrome
C. Fatigue, leukocytosis, DVT
D. DVT, infections, fatigue
E. Infections, leukocytosis, DVT

A

D. DVT, infections, fatigue

35
Q 
Which of the following class of medications used for multiple myeloma requires enrollment in REMS program?
A. Alkylating agents
B. Proteasome Inhibitors
C. Steroids
D. Immunomodulatory agents
E. Monoclonal antibodies
A

D. Immunomodulatory agents (due to embryo-fetal toxicity observed with thalidomide after it being used as a N/V agent in pregnant woman decades ago).

36
Q

True or False: Bortezomib IV has more efficacy compared to Bortezomib SQ.

A

False! They have equal efficacy with SQ having less adverse effects.

37
Q

True or False: In multiple myeloma cells, the combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.

A

True

38
Q

_________ is now the preferred immunomodulatory agent in triple drug regimens due to improved safety profile seen in multiple studies.
A. Thalidomide
B. Lenalidomide
C. Pomalidomide

A

B. Lenalidomide

Oncology Exam 3 (3 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions